Provectus Biopharmaceuticals, Inc. (PVCT) Stock Analysis
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Provectus Biopharmaceuticals, Inc. (PVCT) trades at $0.055 with AI Score 45/100 (Grade C). Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm focused on developing immunotherapy treatments for various cancers and inflammatory skin conditions. Market cap: $23.1M, Sector: Healthcare.
Price as of Aug 21, 2026 · Last analyzed: Jun 14, 2026Analyst Coverage for PVCT: PVCT does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates PVCT against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
PVCT: 2/3 scored disciplines lean bearish. Dominant signal: Seth Klarman bearish.
How is this calculated? →Why this analysis is different
- A 9-signal quantitative MoonshotScore built from filings, insider activity, and market data — computed from the numbers, not from opinion.
- An AI Council read across up to eight perspectives — value, macro, quantitative, and momentum lenses — that shows where they disagree instead of averaging the tension away.
- Figures come straight from FMP and Yahoo Finance filings data. The AI writes the narrative around the numbers — it never edits the numbers.
Provectus Biopharmaceuticals, Inc. (PVCT) Healthcare & Pipeline Overview
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company specializing in immunotherapy treatments, with a focus on its proprietary halogenated xanthene platform and investigational drugs targeting solid tumors and inflammatory skin conditions, positioning it uniquely within the competitive landscape of cancer therapeutics.
What Is the Investment Thesis for PVCT?
Provectus Biopharmaceuticals, Inc. presents a unique investment thesis driven by its innovative drug pipeline, particularly PV-10 and PH-10, which target significant unmet medical needs in oncology and dermatology. The company is currently engaged in multiple clinical trials, which could serve as key value drivers, especially if positive results are achieved. With a market cap of $23.1M and a gross margin of 96.8%, the company is positioned for potential growth as it advances its therapies through clinical stages. However, the high profit margin of -9775.3% reflects the challenges of being a clinical-stage company, emphasizing the importance of successful trial outcomes and regulatory approvals. Investors should monitor the progress of clinical trials and the potential for uplisting to a more recognized exchange, which could enhance liquidity and visibility.
Based on FMP financials and quantitative analysis
PVCT Key Highlights
Market Cap of $23.1M indicates a small-cap status with potential for growth.
- Gross Margin of 96.8% highlights the high value of its proprietary therapies.
- Profit Margin of -9775.3% reflects the challenges faced by clinical-stage companies.
- Beta of 0.84 suggests lower volatility compared to the broader market.
- No dividend yield, consistent with typical biotechnology firms focused on reinvestment.
Who Are PVCT's Competitors?
PVCT is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| IMV IMV Inc. | $0.82 | +0.00% | $9.63M | — |
| ADAPY Adaptimmune Therapeutics plc | $0.03 | +0.00% | $7.16M | 72 |
| RLYB Rallybio Corporation | $16.60 | -2.35% | $88.1M | 81 |
| ICCC ImmuCell Corporation | $10.09 | -0.39% | $91.3M | 77 |
| JNCE Jounce Therapeutics, Inc. | $1.88 | +0.00% | $99.0M | 71 |
| ORMP Oramed Pharmaceuticals Inc. | $4.79 | +0.00% | $196M | 77 |
| CGEN Compugen Ltd. | $2.65 | +8.61% | $251M | 76 |
| NAGE Niagen Bioscience Inc | $3.15 | -0.63% | $251M | 74 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are PVCT's Key Strengths?
Innovative drug pipeline with a focus on immunotherapy.
- High gross margin indicating potential profitability upon commercialization.
- Experienced management team with a clear strategic vision.
What Are PVCT's Weaknesses?
High profit margin indicating significant operational losses.
- Limited employee base may restrict development capabilities.
- Dependency on clinical trial outcomes for future success.
What Could Drive PVCT Stock Higher?
PVCT catalyst: Clinical trials for PV-10 and PH-10 are currently underway, with results expected to impact the company's future market position.
- Potential partnerships with larger pharmaceutical companies could be announced, enhancing development capabilities.
- Plans for uplisting to a major exchange may be explored, increasing visibility and liquidity.
- Advancements in oral formulations of pharmaceutical-grade rose bengal sodium are being pursued, targeting a wide range of conditions.
What Are the Key Risks for PVCT?
Weak fundamentals — a Piotroski F-Score of 2/9 flags soft profitability, leverage or efficiency.
- High dependence on the success of clinical trials for future revenue generation.
- Regulatory challenges may delay product approvals and market entry.
- Competition from other biotechnology firms developing similar therapies.
- Market volatility affecting investor sentiment towards clinical-stage biotechnology companies.
What Are the Growth Opportunities for PVCT?
- Expansion of Clinical Trials: Provectus is currently advancing multiple clinical trials for PV-10 and PH-10, targeting various solid tumors and inflammatory skin conditions.
- Development of Oral Formulations: The advancement of oral formulations of pharmaceutical-grade rose bengal sodium (cGMP RBS) represents a significant growth opportunity. This product aims to address a wide range of conditions, including adult solid tumors and acute respiratory syndromes, tapping into the growing market for oral cancer therapies, which is projected to grow at a CAGR of 8% over the next five years.
- Potential for Pediatric Market Penetration: With its focus on pediatric solid tumors, Provectus has the opportunity to enter a niche yet critical market. The pediatric oncology market is estimated to grow at a CAGR of 5% through 2028, driven by increased awareness and advancements in treatment options.
- Strategic Partnerships and Collaborations: Establishing partnerships with larger pharmaceutical companies could enhance Provectus's development capabilities and market reach. Collaborations can provide access to additional resources, funding, and expertise, which can accelerate the development of its pipeline products.
- Uplisting to a Major Exchange: The potential for Provectus to uplist from the OTC market to a major exchange such as NASDAQ could significantly increase its visibility and liquidity. This transition could attract institutional investors and improve the company's overall market perception.
What Threats Does PVCT Face?
- Intense competition in the biotechnology sector.
- Regulatory hurdles associated with drug approval processes.
- Market volatility affecting investor sentiment towards biotechnology stocks.
What Are PVCT's Competitive Advantages?
- Proprietary halogenated xanthene platform provides a unique competitive advantage.
- Focus on unmet medical needs in oncology and dermatology enhances market positioning.
- Ongoing clinical trials demonstrate commitment to research and development.
What Does PVCT Do?
Provectus Biopharmaceuticals, Inc., founded in 2002 and initially named Provectus Pharmaceuticals, Inc., is a clinical-stage biotechnology firm headquartered in Knoxville, Tennessee. The company is dedicated to pioneering immunotherapy treatments utilizing its proprietary halogenated xanthene platform. Among its key developments is PV-10, an experimental autolytic cancer immunotherapy currently being investigated for a variety of adult solid tumor malignancies, including melanoma and several gastrointestinal cancers, such as hepatocellular carcinoma and metastatic colorectal cancer. Additionally, PV-10 is being explored for pediatric solid tumors like neuroblastoma and Ewing sarcoma. Provectus is further advancing oral formulations of pharmaceutical-grade rose bengal sodium (cGMP RBS), which aims to address a wide range of conditions, including adult solid tumors, pediatric blood cancers, acute respiratory syndromes, and infections caused by multi-drug resistant bacteria. The company is also developing PH-10, an investigational immuno-dermatology agent targeting inflammatory skin conditions such as psoriasis and atopic dermatitis. Since its rebranding in December 2013, Provectus has focused on establishing itself as a leader in the biotechnology sector, particularly in immunotherapy, demonstrating a commitment to research and development through ongoing clinical trials.
What Products and Services Does PVCT Offer?
- Develops immunotherapy treatments for various cancers and inflammatory skin conditions.
- Focuses on proprietary halogenated xanthene platform for drug development.
- Key product PV-10 is an experimental autolytic cancer immunotherapy.
- Advances oral formulations of pharmaceutical-grade rose bengal sodium.
- Targets a broad spectrum of conditions, including solid tumors and infections.
- Conducts clinical trials to validate the efficacy of its therapies.
How Does PVCT Make Money?
- Primarily generates revenue through the development and potential commercialization of innovative therapies.
- Focuses on clinical trial outcomes to advance products toward regulatory approval.
- Explores partnerships and collaborations to enhance development and distribution capabilities.
What Industry Does PVCT Operate In?
The biotechnology industry is characterized by rapid innovation and significant investment in research and development, particularly in the fields of oncology and immunotherapy. The global cancer therapeutics market is projected to grow substantially, driven by increasing cancer prevalence and advancements in treatment modalities. Provectus Biopharmaceuticals, Inc. operates in a competitive landscape alongside other biotechnology firms, focusing on immunotherapy, which is gaining traction due to its potential for personalized medicine. The company's unique approach with its halogenated xanthene platform positions it to capitalize on the growing demand for effective cancer treatments.
Who Are PVCT's Key Customers?
- Healthcare providers and institutions involved in cancer treatment.
- Patients seeking innovative therapies for solid tumors and inflammatory skin conditions.
- Pharmaceutical partners interested in collaboration for drug development.
Financial Health
Provectus Biopharmaceuticals, Inc.'s Piotroski F-Score is 2/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny.
PVCT Valuation & Market Position
With a $23.1M market cap, Provectus Biopharmaceuticals, Inc. sits in the micro-cap segment of the market. Relative to its peer group, PVCT's quantitative score of 45/100 is below the peer average of 75/100.
Key Financial Metrics
Return on equity for Provectus Biopharmaceuticals, Inc. stands at 89.6%, a gauge of how efficiently it converts shareholder capital into profit. Its free cash flow yield is -9.0%, a gauge of the cash the business throws off relative to its market value. A current ratio of 0.06 means current liabilities exceed short-term assets, a liquidity point worth watching. Its earnings yield is -19.6%, the inverse of the P/E and a quick read on earnings relative to price.
Company Profile
Provectus Biopharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in Knoxville, US. The company is led by CEO Edward V. Pershing. PVCT has traded publicly since 1997.
PVCT Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis · FY 2025
Bull Case vs Bear Case
Bull Case
- Recent insider buying suggests confidence in the company's future prospects, indicating that those closest to the company believe in its potential.
- Community sentiment has shifted positively, with discussions highlighting the company's innovative treatments and their potential market impact.
- Positive developments in clinical trial results have generated excitement among investors, reflecting a growing belief in the company's therapeutic advancements.
- Increased media coverage around the company's breakthroughs has enhanced visibility, attracting interest from new investors.
Bear Case
- Concerns about the competitive landscape are rising, as other firms advance similar therapies, potentially overshadowing Provectus's innovations.
- Recent volatility in the biotech sector has led to cautious sentiment among investors, with many opting for safer investments amid uncertainty.
- Some community members express skepticism regarding the timelines for product approvals, fearing delays could hinder growth prospects.
- Inconsistent communication from the company has raised questions about transparency, leading to a lack of trust among some investors.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · March 2026
PVCT Latest News
No recent news available for PVCT.
PVCT Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for PVCT.
Price Targets
Wall Street price target analysis for PVCT.
PVCT MoonshotScore
What does this score mean?
The MoonshotScore rates PVCT 0-100 on quantitative fundamentals — growth, financial health, valuation, momentum, and risk.
Leadership: Edward V. Pershing
CEO
Edward V. Pershing has a significant background in the biotechnology and pharmaceutical industries, having held various leadership roles throughout his career. He has extensive experience in corporate management, strategic planning, and product development, which has been instrumental in guiding Provectus Biopharmaceuticals towards its current focus on innovative therapies. His educational background and professional credentials further enhance his capability in leading the company.
Track Record: Under Edward V. Pershing's leadership, Provectus has advanced its clinical pipeline, focusing on key investigational drugs such as PV-10 and PH-10. His strategic decisions have helped position the company within the competitive biotechnology landscape, emphasizing research and development.
PVCT OTC Market Information
The OTC Other tier represents stocks that do not meet the criteria for more regulated exchanges like NYSE or NASDAQ. These stocks may have lower liquidity, less stringent reporting requirements, and higher volatility, making them riskier investments. Investors should be cautious and conduct thorough due diligence when considering such stocks.
- OTC Tier: OTC Other
- Limited liquidity may result in increased price volatility.
- Regulatory scrutiny can impact the company's operations and stock performance.
- Dependence on clinical trial outcomes introduces significant risk.
- Verify the company's clinical trial progress and results.
- Assess the financial health and cash runway of Provectus.
- Review any potential partnerships or collaborations in development.
- Monitor regulatory developments and market conditions affecting the biotechnology sector.
- Evaluate the management team's experience and track record.
- Established history since 2002, indicating stability.
- Focused research and development efforts on innovative therapies.
- Engagement in clinical trials demonstrates commitment to advancing its pipeline.
Provectus Biopharmaceuticals, Inc. Healthcare Stock: Key Questions Answered
What does the AI Score mean for PVCT?
PVCT holds an AI Score of 45/100 (Grade: C). This is an educational research signal, not a buy or sell recommendation. Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology firm focused on developing immunotherapy treatments for various cancers and inflammatory skin conditions. The company leverages …
What does Provectus Biopharmaceuticals, Inc. do?
Provectus Biopharmaceuticals, Inc. is a clinical-stage biotechnology company focused on developing innovative immunotherapy treatments for various cancers and inflammatory skin conditions. Its key products include PV-10, an experimental cancer immunotherapy, and PH-10, aimed at treating inflammatory skin conditions. The company leverages its proprietary halogenated xanthene platform to advance its drug pipeline.
What is Provectus Biopharmaceuticals, Inc.'s drug pipeline status?
Provectus Biopharmaceuticals, Inc. is actively engaged in clinical trials for its key investigational drugs, PV-10 and PH-10. These drugs are being evaluated for their efficacy in treating various solid tumors and inflammatory skin conditions. The company is focused on achieving positive trial results, which are critical for advancing its products toward regulatory approval and commercialization.
What are the main risks for PVCT?
Provectus Biopharmaceuticals, Inc. faces several risks, including high dependence on the success of its clinical trials, which are essential for future revenue generation. Additionally, regulatory challenges could delay product approvals, impacting the company's market entry. The competitive landscape poses a threat, as other biotechnology firms are developing similar therapies, and market volatility may affect investor sentiment towards clinical-stage companies.
What are the key factors to evaluate for PVCT?
Provectus Biopharmaceuticals, Inc. (PVCT) holds an AI score of 45/100 (low). presents a unique investment thesis driven by its innovative drug pipeline, particularly PV-10 and PH-10, which target significant unmet medical needs in oncology and dermatology. Not financial advice.
How frequently does PVCT data refresh on this page?
PVCT's price was last updated on Aug 21, 2026 and refreshes on page view during U.S. market hours — it is not a real-time exchange feed. Fundamentals update after quarterly filings; the MoonshotScore recalculates nightly; news aggregates continuously.
What has driven PVCT's recent stock price performance?
Provectus Biopharmaceuticals, Inc. (PVCT) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Innovative drug pipeline with a focus on immunotherapy. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider PVCT overvalued or undervalued right now?
Provectus Biopharmaceuticals, Inc. (PVCT) has no trailing P/E available here, so lean on price-to-sales and cash flow in the Financials tab. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
How do I research PVCT before investing?
Before investing in Provectus Biopharmaceuticals, Inc. (PVCT), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) analyst consensus ratings and price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- Data is based on the latest available information and may be subject to change.